Tuesday - December 24, 2024
U.S. FDA Accepts GSK's Submission for the Use of Nucala in COPD
December 10, 2024
LONDON, England, Dec. 10 (TNSres) -- GSK (formerly GlaxoSmithKline), a biopharmaceutical company, issued the following news release on Dec. 9, 2024:

* * *

- Submission supported by MATINEE data showing significant and clinically meaningful reduction in annualised rate of moderate/severe exacerbations compared with placebo

- Nucala could be the first approved biologic with monthly dosing for patients with COPD

- COPD affects more than 14 million . . .

Targeted News Service Document Request Form

This document is available to you by e-mail if you complete the form below with relevant information. There may be a fee for this article or ongoing service of similar materials. We will be in touch shortly.

Name:
What's your
Affiliation		 Government Newspaper / Media Business
Public Policy Individual / Student Educators
Email:
Phone:
Organization, if any:
State/Country you are in:
Additonal questions
or comments:

Click here for more information about our products

Click here for more information about our products